FTC
-
How the FTC Is Tackling ‘Below the Radar’ Healthcare Deals
The Federal Trade Commission only gets notified when a merger/acquisition deal value is above $100-$110 million, so smaller deals nonetheless lead to a slow consolidation of the market. In conference remarks, FTC Chair Lina Khan outlined the ways in which the agency is trying to counter this phenomenon.
-
GoodRx Illegally Sold Users’ Data to Google & Facebook, FTC Says
GoodRx failed to notify users that it sold their personal health information to Google, Facebook and other tech companies, the FTC claimed. The agency filed an order that prohibits GoodRx from sharing its users’ data with third parties for advertising purposes and requires the company to pay a $1.5 million penalty. GoodRx agreed to pay the settlement but did not admit to wrongdoing.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
FTC blocks merger of two NJ hospitals less than a mile apart
This is the third complaint the FTC filed against proposed hospital mergers so far this year.
-
With the FTC’s conditional approval, Medtronic completes its $1.1B acquisition of Intersect ENT
To get approval for the deal, Medtronic agreed to sell an Intersect subsidiary to soothe the FTC’s concerns.
-
Health apps could face big fines if they don’t disclose privacy breaches
The agency reminded health apps and wearables companies that they must disclose any breach of users’ health information, even if they are not a HIPAA covered entity. Companies that fail to disclose a breach could face thousands of dollars per day in fines.
-
Hackensack Meridian Health, Englewood Health appeal court decision to block merger
The FTC sued to block the merger between the two New Jersey-based health systems and won a preliminary injunction earlier this month. But the providers believe that the merger would not raise prices or stifle competition — like the FTC alleges it would — and have filed an appeal.
-
Einstein Healthcare Network, Jefferson Health to merge after FTC drops challenge
The Federal Trade Commission is no longer opposing the proposed merger between Einstein Healthcare Network and Jefferson Health. Nearly three years after it was first announced, the deal can now move forward uncontested and will result in an 18-hospital system.
-
Why hospitals want CMS, FTC to examine two UnitedHealthcare policies
Two UnitedHealthcare policies have raised several concerns among providers, including that they may display anti-competitive behavior and could block patient access to certain healthcare services. The American Hospital Association is asking the FTC and CMS to review and potentially block these policies.
-
Period-tracking app settles FTC charges that it misled users about privacy
Flo, a popular period-tracking app, reached a settlement with the FTC over allegations that it misled users about how their health information would be shared. As part of the settlement, the startup is required to conduct an independent review of its privacy practices.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Zoom reaches settlement over encryption claims
Video conferencing company Zoom reached a settlement with the Federal Trade Commission over claims that the company used end-to-end encryption in its video calls, when it reportedly used a lower level of security.
-
FDA, FTC look to crack down on tactics that they say thwart biosimilars
In a joint statement, FDA Commissioner Stephen Hahn and FTC Chairman Joseph Simons said they would look into anticompetitive practices like preventing biosimilar makers from obtaining product samples and misleading communications about biosimilars’ safety and efficacy.
-
Roche completes acquisition of Spark Therapeutics as regulators give go-ahead
The Federal Trade Commission and its U.K. counterpart concluded that Roche would not likely have an incentive to delay or discontinue development of Spark’s hemophilia A gene therapy. Roche markets a monoclonal antibody for the same disease.
-
Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal
Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.
-
Surescripts fires back at Amazon by kicking vendor ReMy Health off its network
Surescripts says that instead of using its own National Provider Identification (NPI) number, Pillpack fraudulently used NPIs that was associated with random healthcare providers.
-
Amazon may file suit against Surescripts for access to patient data
CNBC cited unnamed sources who state that PillPack will be blocked from accessing data about a patient’s list of medications and prescription history, which it uses to accurately and safely send out medications to customers.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
